Welcome to our dedicated page for X4 Pharmaceuticals news (Ticker: XFOR), a resource for investors and traders seeking the latest updates and insights on X4 Pharmaceuticals stock.
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR) is a biopharmaceutical company focused on rare hematology diseases and rare diseases of the immune system, with a core emphasis on CXCR4‑targeted therapies. Its news flow frequently centers on the development and commercialization of mavorixafor, an orally available CXCR4 antagonist marketed in the United States as XOLREMDI® in its first indication and under active investigation in chronic neutropenia and other rare hematologic conditions.
On this page, readers can review news items that X4 has issued about its clinical, corporate and financial milestones. These include updates on the global, pivotal Phase 3 4WARD trial in chronic neutropenia, where mavorixafor is being evaluated as an oral, once‑daily therapy with or without G‑CSF in people with congenital, acquired primary autoimmune, or idiopathic chronic neutropenia who experience recurrent and serious infections. News coverage also highlights Phase 2 trial data demonstrating durable increases in absolute neutrophil count, reductions or discontinuation of injectable G‑CSF in many participants, and safety observations consistent with previous mavorixafor studies.
Investors and observers will also find press releases on financing transactions such as private placements of common stock and pre‑funded warrants, underwritten public offerings, and an equity purchase agreement with Lincoln Park Capital Fund, LLC. These announcements describe how X4 intends to fund the pivotal development of mavorixafor in chronic neutropenia and support its commercialization activities. Additional news items cover organizational restructuring, workforce reductions, leadership and board changes, and participation in healthcare and hematology conferences where X4 presents clinical data and corporate updates.
By following XFOR news, readers can track how X4 Pharmaceuticals reports progress in its rare hematology programs, interprets emerging clinical results for mavorixafor, and manages its capital structure and operations as it advances its CXCR4‑based therapeutic strategy.
X4 Pharmaceuticals (XFOR) announced upcoming presentations at the 66th ASH Annual Meeting, featuring a trial-in-progress poster on their Phase 3 4WARD clinical trial of mavorixafor for chronic neutropenia (CN). The trial is evaluating the oral CXCR4 antagonist as both monotherapy and combined with injectable G-CSF.
The 52-week study aims to enroll 150 participants across 90-110 sites in 20-25 countries. It's designed as a randomized, double-blind, placebo-controlled trial for patients with congenital, acquired primary autoimmune, or idiopathic CN experiencing recurrent infections.
The company will also present preclinical data on CXCR4 antagonism's potential to correct neutropenia and bone marrow neutrophil accumulation.
X4 Pharmaceuticals (XFOR) has announced the issuance of inducement awards to new employees under its 2019 Inducement Equity Incentive Plan. The awards consist of options to purchase 396,824 shares of common stock at an exercise price of $0.371 per share, equal to the closing price on December 2, 2024.
The options have a ten-year term and will vest over four years, with 25% vesting after 12 months and the remainder vesting monthly over the following 36 months, contingent on continued employment. These awards were granted as inducement material for new employees and approved by X4's Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).
X4 Pharmaceuticals (Nasdaq: XFOR), focused on rare immune system diseases, announces its participation in the 36th Annual Piper Sandler Healthcare Conference in New York. The company will engage in a fireside chat on Tuesday, December 3, 2024, at 11:00 AM ET at the Lotte New York Palace. The event will be available via webcast through X4's investor relations website, with a replay option post-conference. Management will also be available for one-on-one meetings with investors, which can be arranged through Piper Sandler representatives.
X4 Pharmaceuticals (Nasdaq: XFOR), focused on rare immune system diseases, announced its participation in the Stifel 2024 Healthcare Conference in New York. The company will engage in a fireside chat on Monday, November 18, 2024, at 4:10 PM ET at the Lotte New York Palace. A live webcast will be available through X4's website's investor section, with a replay accessible after the event. The company will also be available for one-on-one meetings with investors, which can be arranged through Stifel representatives.
X4 Pharmaceuticals (XFOR) reported Q3 2024 financial results and corporate updates. The company announced positive Phase 2 results for mavorixafor in chronic neutropenia (CN) and continues enrollment in its Phase 3 4WARD trial, expected to complete by mid-2025. Following XOLREMDI's U.S. approval in April 2024, X4 generated initial product revenue of $0.6 million. The company reported a net loss of $36.7 million and holds $135.8 million in cash, sufficient to support operations into late 2025. X4 plans to submit a Marketing Authorization Application to the EMA for WHIM syndrome by early 2025.
X4 Pharmaceuticals (XFOR) announced positive results from its completed six-month Phase 2 trial of mavorixafor in Chronic Neutropenia (CN). The study demonstrated that mavorixafor durably increased participants' mean absolute neutrophil counts (ANC) to normal levels. In combination therapy, it enabled substantial G-CSF dosing reductions (52% at Month 3 and 70% at Month 6) while maintaining normal ANC levels. A sub-study showed that neutrophils mobilized by mavorixafor were as functional as those from healthy donors. The drug was generally well tolerated with no drug-related serious adverse events reported.
X4 Pharmaceuticals (XFOR) has granted inducement awards to new employees under its 2019 Inducement Plan. The awards consist of options to purchase 271,764 shares of common stock at an exercise price of $0.5002 per share, equal to the closing price on October 31, 2024. The options have a ten-year term and will vest over four years, with 25% vesting after 12 months and the remainder vesting monthly over 36 months, contingent on continued employment. These grants were made in accordance with Nasdaq Listing Rule 5635(c)(4).
X4 Pharmaceuticals (Nasdaq: XFOR) has announced it will report its third-quarter 2024 financial results and present findings from its completed Phase 2 clinical trial of mavorixafor in chronic neutropenia patients on November 13, 2024. The company will host a conference call and webcast at 8:00 a.m. ET on the same day. The presentation will be accessible via phone and through the company's investor relations website, with a replay available afterward.
X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare immune system diseases, has announced the issuance of inducement awards to new employees under its 2019 Inducement Equity Incentive Plan. The awards, approved by X4's Compensation Committee, consist of options to purchase 744,468 shares of X4's common stock. These options have a ten-year term and an exercise price of $0.6693 per share, equal to the closing price on September 30, 2024.
The options will vest over a four-year period, with 25% vesting after 12 months and the remainder vesting monthly over the following 36 months, subject to continued employment. These awards were granted in accordance with Nasdaq Listing Rule 5635(c)(4) as an inducement for new employees joining X4 Pharmaceuticals.
X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare immune system diseases, has announced the issuance of inducement awards to new employees under its 2019 Inducement Equity Incentive Plan. The awards, granted on August 30, 2024, consist of options to purchase 230,588 shares of X4's common stock. These options have a ten-year term and an exercise price of $0.70 per share, equal to the closing price of X4's stock on the grant date. The options will vest over four years, with 25% vesting after 12 months and the remainder vesting monthly over the following 36 months, subject to continued employment. This grant aligns with Nasdaq Listing Rule 5635(c)(4) and was approved by X4's Compensation Committee.